Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway

IntroductionThe incidence of diabetes is rising annually, significantly impacting public health and imposing a substantial economic burden on society. Ophiopogonin D (Op D) exhibits certain hypoglycemic effects; however, its mechanisms remain unclear.Methodsβ-cell dedifferentiation, distinct from β-...

Full description

Bibliographic Details
Published in:Frontiers in Pharmacology
Main Authors: Haoxiang Sun, Ruixiang Tan, Yongzhi Sun, Yimeng Li, Ying Xie, Cheng Zhang, Jianping Song, Wei Zhu, Jiuyao Zhou, Changsheng Deng, Manxue Mei
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1563201/full
_version_ 1849405227393875968
author Haoxiang Sun
Ruixiang Tan
Yongzhi Sun
Yimeng Li
Ying Xie
Cheng Zhang
Jianping Song
Wei Zhu
Jiuyao Zhou
Changsheng Deng
Manxue Mei
author_facet Haoxiang Sun
Ruixiang Tan
Yongzhi Sun
Yimeng Li
Ying Xie
Cheng Zhang
Jianping Song
Wei Zhu
Jiuyao Zhou
Changsheng Deng
Manxue Mei
author_sort Haoxiang Sun
collection DOAJ
container_title Frontiers in Pharmacology
description IntroductionThe incidence of diabetes is rising annually, significantly impacting public health and imposing a substantial economic burden on society. Ophiopogonin D (Op D) exhibits certain hypoglycemic effects; however, its mechanisms remain unclear.Methodsβ-cell dedifferentiation, distinct from β-cell apoptosis, is a pathogenic mechanism we aim to explore regarding Op D’s regulatory effects. We established an animal model of β-cell dedifferentiation to assess Op D’s impact on glucose tolerance, blood glucose levels, and insulin secretion. We employed immunohistochemistry and immunofluorescence to analyze the expression levels of dedifferentiation-related proteins. Additionally, we created an in vitro β-cell dedifferentiation model using INS-1 cells to evaluate Op D’s influence on insulin secretion and dedifferentiation. Transcriptomic analysis was conducted to explore potential mechanisms by which Op D ameliorates dedifferentiation, with further validation via Western blotting and immunofluorescence. Flow cytometry, fluorescence microscopy, and related assays were used to assess Op D’s effects on oxidative stress. Endoplasmic reticulum (ER) tracing agents marked the ER, and laser confocal microscopy examined ER morphology, with ER stress inducers and inhibitors employed to clarify Op D’s mechanisms.ResultsResults indicated that Op D reduced blood glucose levels, improved glucose tolerance, enhanced insulin secretion, mitigated pancreatic atrophy, and increased PDX1 and FOXO1 expression levels. Furthermore, Op D inhibited ER stress, decreased GRP78 expression, reduced NGN3 levels, elevated PDX1, NKX6.1, and MAFA expression, and decreased oxidative stress-related products (ROS, MDA) while increasing SOD and GSH levels.DiscussionThese findings demonstrate that Op D can improve β-cell dedifferentiation by modulating the GRP78/ROS/PDX1 pathway to inhibit ER stress.
format Article
id doaj-art-e249eea7604a41e596941dbfead95313
institution Directory of Open Access Journals
issn 1663-9812
language English
publishDate 2025-04-01
publisher Frontiers Media S.A.
record_format Article
spelling doaj-art-e249eea7604a41e596941dbfead953132025-08-20T03:53:42ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-04-011610.3389/fphar.2025.15632011563201Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathwayHaoxiang Sun0Ruixiang Tan1Yongzhi Sun2Yimeng Li3Ying Xie4Cheng Zhang5Jianping Song6Wei Zhu7Jiuyao Zhou8Changsheng Deng9Manxue Mei10Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaSci-Tech Industrial Park, Guangzhou University of Chinese Medicine, Guangzhou, ChinaDermatology Hospital of Southern Medical University, Guangzhou, ChinaThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, ChinaArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, ChinaArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, ChinaIntroductionThe incidence of diabetes is rising annually, significantly impacting public health and imposing a substantial economic burden on society. Ophiopogonin D (Op D) exhibits certain hypoglycemic effects; however, its mechanisms remain unclear.Methodsβ-cell dedifferentiation, distinct from β-cell apoptosis, is a pathogenic mechanism we aim to explore regarding Op D’s regulatory effects. We established an animal model of β-cell dedifferentiation to assess Op D’s impact on glucose tolerance, blood glucose levels, and insulin secretion. We employed immunohistochemistry and immunofluorescence to analyze the expression levels of dedifferentiation-related proteins. Additionally, we created an in vitro β-cell dedifferentiation model using INS-1 cells to evaluate Op D’s influence on insulin secretion and dedifferentiation. Transcriptomic analysis was conducted to explore potential mechanisms by which Op D ameliorates dedifferentiation, with further validation via Western blotting and immunofluorescence. Flow cytometry, fluorescence microscopy, and related assays were used to assess Op D’s effects on oxidative stress. Endoplasmic reticulum (ER) tracing agents marked the ER, and laser confocal microscopy examined ER morphology, with ER stress inducers and inhibitors employed to clarify Op D’s mechanisms.ResultsResults indicated that Op D reduced blood glucose levels, improved glucose tolerance, enhanced insulin secretion, mitigated pancreatic atrophy, and increased PDX1 and FOXO1 expression levels. Furthermore, Op D inhibited ER stress, decreased GRP78 expression, reduced NGN3 levels, elevated PDX1, NKX6.1, and MAFA expression, and decreased oxidative stress-related products (ROS, MDA) while increasing SOD and GSH levels.DiscussionThese findings demonstrate that Op D can improve β-cell dedifferentiation by modulating the GRP78/ROS/PDX1 pathway to inhibit ER stress.https://www.frontiersin.org/articles/10.3389/fphar.2025.1563201/fullophiopogonin DdedifferentiationdiabetesGRP78/ROS/PDX1unfolded protein response
spellingShingle Haoxiang Sun
Ruixiang Tan
Yongzhi Sun
Yimeng Li
Ying Xie
Cheng Zhang
Jianping Song
Wei Zhu
Jiuyao Zhou
Changsheng Deng
Manxue Mei
Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway
ophiopogonin D
dedifferentiation
diabetes
GRP78/ROS/PDX1
unfolded protein response
title Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway
title_full Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway
title_fullStr Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway
title_full_unstemmed Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway
title_short Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway
title_sort ophiopogonin d improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the grp78 ros pdx1 signaling pathway
topic ophiopogonin D
dedifferentiation
diabetes
GRP78/ROS/PDX1
unfolded protein response
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1563201/full
work_keys_str_mv AT haoxiangsun ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT ruixiangtan ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT yongzhisun ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT yimengli ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT yingxie ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT chengzhang ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT jianpingsong ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT weizhu ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT jiuyaozhou ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT changshengdeng ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway
AT manxuemei ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway